文献速递乳腺癌妇科肿瘤泌尿男性生殖肿瘤

BRCA基因回复突变荟萃分析:DNA末端连接修复驱动治疗耐药

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
PubMed 文献 · Ann Oncol · 2020-10-19

该研究分析了327例携带BRCA1/2突变的肿瘤患者在铂类或PARPi治疗进展后的测序数据,发现86例(26.0%)存在回复突变。回复突变多由微同源介导的DNA末端连接修复产生,尤其在BRCA2中显著,提示抑制该通路可能延缓耐药。

要点

  • BRCA回复突变是铂类/PARPi耐药的明确机制,在进展患者中占26.0%。
  • BRCA1/2外显子11编码区大多可缺失而不影响耐药产生。
  • 突变性DNA末端连接修复是回复突变的关键驱动因素,尤其BRCA2。

核心结论

  • 药理学抑制DNA末端连接修复通路可能通过防止BRCA回复突变来提高药物耐久性。
  • 回复突变导致BRCA蛋白低功能版本表达时,靶向DNA复制应激反应的药物可能提供新治疗机会。

研究设计与样本

  • 荟萃分析,分析已发表的BRCA基因测序数据(肿瘤或循环肿瘤DNA),共327例携带BRCA1/2突变且进展于铂类或PARPi治疗的患者。
  • 患者包括234例卵巢癌、27例乳腺癌、13例胰腺癌、11例前列腺癌和42例原发灶不明肿瘤。

主要发现

  • 86例患者(26.0%)中共鉴定出269例回复突变。
  • BRCA1和BRCA2外显子11编码的大部分氨基酸序列对产生铂类或PARPi耐药并非必需,而其他区域更难耐受大规模氨基酸缺失。
  • 回复事件周围缺失侧翼的DNA序列微同源显著累积,提示突变性末端连接修复通路在产生回复突变中起关键作用,尤其在BRCA2中。

临床怎么用

  • 对铂类或PARPi进展的BRCA突变肿瘤患者,应考虑检测回复突变以解释耐药。
  • 回复突变由DNA末端连接修复驱动,提示联合抑制该通路可能延缓耐药,但需临床验证。
  • 回复突变导致低功能BRCA蛋白表达时,靶向DNA复制应激反应的药物可能成为潜在策略。

局限性

  • 仅基于已发表测序数据的荟萃分析,可能存在发表偏倚和数据异质性。
  • 样本来自多种肿瘤类型且包括原发灶不明肿瘤,亚组结论需谨慎解读。
  • 回复突变检测方法和测序深度未在摘要中统一说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Germline mutations in the BRCA1 or BRCA2 (BRCA) genes predispose to hereditary breast and ovarian cancer and, mostly in the case of BRCA2, are also prevalent in cases of pancreatic and prostate malignancies. Tumours from these patients tend to lose both copies of the wild-type BRCA gene, which makes them exquisitely sensitive to platinum drugs and poly(ADP-ribose) polymerase inhibitors (PARPi), treatments of choice in these disease settings. Reversion secondary mutations with the capacity of restoring BRCA protein expression have been documented in the literature as bona fide mechanisms of resistance to these treatments. PATIENTS AND METHODS: We analysed published sequencing data of BRCA genes (from tumour or circulating tumour DNA) in 327 patients with tumours harbouring mutations in BRCA1 or BRCA2 (234 patients with ovarian cancer, 27 with breast cancer, 13 with pancreatic cancer, 11 with prostate cancer and 42 with a cancer of unknown origin) that progressed on platinum or PARPi treatment. RESULTS: We describe 269 cases of reversion mutations in 86 patients in this cohort (26.0%). Detailed analyses of the reversion events highlight that most amino acid sequences encoded by exon 11 in BRCA1 and BRCA2 are dispensable to generate resistance to platinum or PARPi, whereas other regions are more refractory to sizeable amino acid losses. They also underline the key role of mutagenic end-joining DNA repair pathways in generating reversions, especially in those affecting BRCA2, as indicated by the significant accumulation of DNA sequence microhomologies surrounding deletions leading to reversion events. CONCLUSIONS: Our analyses suggest that pharmacological inhibition of DNA end-joining repair pathways could improve durability of drug treatments by preventing the acquisition of reversion mutations in BRCA genes. They also highlight potential new therapeutic opportunities when reversions result in expression of hypomorphic versions of BRCA proteins, especially with agents targeting the response to DNA replication stress.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Tobalina L, Armenia J, Irving E, et al. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2020. PMID: 33091561. doi:10.1016/j.annonc.2020.10.470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。